France· FR:62599329
CALQUENCE 100 mg, gélule
A medicinal product containing acalabrutinib, registered in France by ASTRAZENECA AB, on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- ACALABRUTINIB
- Manufacturer
- ASTRAZENECA AB
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip133400930212929plaquette(s) aluminium de 60 gélule(s)EUR 4.29
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Acalabrutinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomCalquence 100mg capsulesAstraZeneca UK Ltd
- CzechiaCALQUENCEAstraZeneca AB, Södertälje
- SpainCALQUENCE 100 MG CAPSULAS DURASAstrazeneca Ab
- FinlandCalquenceAstraZeneca AB
- IrelandCalquence 100 mg hard capsulesAstraZeneca AB
- IcelandCalquenceAstraZeneca AB*
- NetherlandsCalquence 100 mg harde capsulesAstraZeneca AB
- PolandCalquenceAstraZeneca AB
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Calquence
- Liechtenstein · Calquence
- Norway · Calquence
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/bf80c186-acb5-409f-91dd-05d30dcc02a2 GET /v1/drugs/bf80c186-acb5-409f-91dd-05d30dcc02a2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62599329",
"date_amm": "2020-11-05",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/20/1479",
"substance": "ACALABRUTINIB",
"statut_amm": "Autorisation active",
"statut_bdm": "Warning disponibilité",
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Non commercialisée",
"surveillance_renforcee": "Non"
}See everything about acalabrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.